← Leaderboards
Vu Nguyen Ngo
Beckman Research Institute/City Of Hope
$2,153,609
Attributed
$2,153,609
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $501.2K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,153,609 · 2
By mechanism
R01$1,989,049 · 1
R03$164,560 · 1
Top collaborators
No co-investigators on record.
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Mingye Feng$6,090,660
Others in their field
Other Emerging Leaders on “S Lymphoma”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$22,138,591
- Leonard Freedman · Leidos Biomedical Research, Inc.$10,332,151
- Kathleen Nicol · Research Inst Nationwide Children'S Hosp$7,187,946
- Javeed Iqbal · University Of Nebraska Medical Center$5,566,166
- John Karijolich · Vanderbilt University Medical Center$5,446,739
Research focus
S LymphomaOverexpressionChimeric Antigen ReceptorIn VitroMantle Cell LymphomaOncogenicGene Expression ProfilingEffective TherapyImmunotherapeutic AgentIntegral Membrane ProteinLymphomaLymphoma CellChimeric Antigen Receptor T CellsNon-Hodgkin&AposIn VivoCytoplasmic TailB-Cell LymphomasCeacam1Genome-WideB-LymphocytesB Lymphoid MalignancyImmunotherapyItimPharmaceutical Preparations
Grant awards (7)
The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma$401,561
R01 · FY2025 · CA · contact PI
The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma$381,482
R01 · FY2024 · CA · contact PI
The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma$393,530
R01 · FY2023 · CA · contact PI
The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma$393,530
R01 · FY2022 · CA · contact PI
The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma$418,946
R01 · FY2021 · CA · contact PI
Characterization of CEACAM1 as a novel therapeutic in mantle cell lymphoma$82,280
R03 · FY2021 · CA · contact PI
Characterization of CEACAM1 as a novel therapeutic in mantle cell lymphoma$82,280
R03 · FY2020 · CA · contact PI